Sobi North America, a unit of Swedish Orphan Biovitrum AB , said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug for treatment of high-risk hospitalized COVID-19 patients.
https://www.pharmalive.com/wp-content/uploads/2022/11/SOBI_logo.jpg6281200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-11-10 07:58:032022-11-10 11:29:17U.S. authorizes Sobi’s drug to treat COVID-19 in high-risk patients